

Date: 3rd February, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001
Bandra (East), Mumbai - 400051

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex

Dear Sir/Madam,

Sub: Outcome of Board Meeting of MedPlus Health Services Limited held on 3rd February, 2023

This is to inform you that the Board of Directors of the Company at its Meeting held on 3rd February, 2023 have approved the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended on 31st December, 2022.

This is intimation pursuant to Regulations 30, 33, read with Para A. 4. (h) of Part A and Para A. (16) (b) of Part B of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

We are enclosing the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended 31st December, 2022, along with the Limited Review Report thereon, issued by the Statutory Auditors, M/s B S R & Associates LLP, Chartered Accountants.

The Meeting of the Board of Directors of the Company commenced at 04:30 P.M. and concluded at 5:45 P.M.

This intimation is also being uploaded on the Company's website at www.medplusindia.com.

You are requested to kindly note the same.

This is for your information.

For and on behalf of MedPlus Health Services Limited

Shilpi Keswani
Company Secretary

Encl: a/a

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Onwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report (Continued)

MedPlus Health Services Limited

6. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 2,814.47 million and Rs. 8,051.52 million, total net profit after tax (before consolidation adjustments) of Rs. 26.86 million and Rs. 70.02 million and total comprehensive income (before consolidation adjustments) of Rs. 26.86 million and Rs 70.02 million, for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial results of 9 Subsidiaries which have not been reviewed, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 1,073.43 million and Rs. 3,016.72 million, total net profit after tax (before consolidation adjustments) of Rs. 24.54 million and Rs. 72.81 million and total comprehensive income (before consolidation adjustments) of Rs. 24.54 million and Rs. 72.81 million for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231W/W-100024



Arpan Jain

Partner

Hyderabad

03 February 2023

Membership No.: 125710

UDIN:23125710BGYPY1851

Limited Review Report (Continued)

MedPlus Health Services Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	MedPlus Health Services Limited	Holding
2	Optival Health Solutions Private Limited	Subsidiary
3	MHS Pharmaceuticals Private Limited	Subsidiary
4	Nova Sud Pharmaceuticals Private Limited	Subsidiary
5	Wynclark Pharmaceuticals Private Limited	Subsidiary
6	Kalyani Meditimes Private Limited	Subsidiary
7	Clearancekart Private Limited	Subsidiary
8	Sai Sridhar Pharma Private Limited	Subsidiary
9	Venkata Krishna Enterprises Private Limited	Subsidiary
10	Shri Banashankari Pharma Private Limited	Subsidiary
11	Deccan Medisales Private Limited	Subsidiary
12	Sidson Pharma Distributors Private Limited	Subsidiary
13	MedPlus Insurance Brokers Private Limited	Subsidiary

A

MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited)
CIN - L85110TG2006PLC051845

Regd. Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037.
Statement of Unaudited Consolidated Financial Results for the Quarter & Nine Months period ended December 31, 2022

(Rs. in Millions)


S.No.	Particulars	Quarter ended			Nine Months ended		Year ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	11,903.14	11,206.25	9,334.53	33,045.93	28,133.72	37,792.79
	Other income	113.61	108.93	73.34	323.84	183.14	313.63
I	Total income	12,016.75	11,315.18	9,407.87	33,369.77	28,316.86	38,106.42
	Expenses						
	Cost of materials consumed	67.64	52.55	35.79	169.54	142.68	194.40
	Purchases of stock-in-trade	9,867.83	9,377.78	7,721.59	27,373.92	23,019.00	31,223.73
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(670.38)	(651.72)	(360.99)	(1,666.36)	(938.02)	(1,594.38)
	Employee benefits expense	1,438.04	1,347.75	1,003.60	3,965.34	2,801.72	3,939.20
	Finance costs	210.82	198.66	165.31	607.58	478.51	664.28
	Depreciation and amortisation expense	457.89	418.70	304.84	1,257.58	852.48	1,193.60
	Other expenses	482.78	483.23	320.22	1,363.08	907.41	1,306.16
II	Total expenses	11,854.62	11,226.95	9,190.36	33,070.68	27,263.78	36,926.99
III	Profit before tax (I-II)	162.13	88.23	217.51	299.09	1,053.08	1,179.43
	Tax expense						
	- Current tax	50.48	24.30	62.02	85.77	267.69	301.24
	- Deferred tax benefit	(22.16)	(0.85)	(13.68)	(22.14)	(47.45)	(68.97)
	- Income Taxes of Earlier Years	-	-	-	-	-	-
IV	Total tax expense	28.32	23.45	48.34	63.63	220.24	232.27
V	Profit after tax (III-IV)	133.81	64.78	169.17	235.46	832.84	947.16
	Other Comprehensive Income (OCI)						
	(i) Items that will not be reclassified to profit or loss						
	- Re-measurement gain / (loss) on employee defined benefit plan	(2.69)	(30.07)	(1.93)	4.93	21.89	23.86
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.68	7.30	0.44	(1.21)	(5.42)	(5.58)
VI	Other comprehensive (loss) / income for the period/year, net of tax	(2.01)	(22.77)	(1.49)	3.72	16.47	18.28
VII	Total comprehensive income for the period/year (V+VI)	131.80	42.01	167.68	239.18	849.31	965.44
VIII	Profit for the period/year attributable to:						
	Shareholders of the Company	134.07	65.66	171.73	231.80	840.74	958.02
	Non-controlling interest	(0.26)	(0.88)	(2.56)	3.66	(7.90)	(10.86)
		133.81	64.78	169.17	235.46	832.84	947.16
IX	Total comprehensive income attributable to:						
	Shareholders of the Company	132.06	42.89	167.85	235.52	854.82	976.12
	Non-controlling interest	(0.26)	(0.88)	(0.17)	3.66	(5.51)	(10.68)
		131.80	42.01	167.68	239.18	849.31	965.44
X	Paid-up Capital						
	Equity Share Capital	238.60	238.60	238.60	238.60	238.60	238.60
XI	Other Equity						13,939.12
XII	Earnings per equity share (for the period/quarter not annualised)						
	Basic (In absolute Rs.)	1.12	0.55	1.53	2.16	7.66	8.55
	Diluted (In absolute Rs.)	1.12	0.55	1.52	2.16	7.44	8.52
XIII	Face value per share						
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00	2.00	2.00



**Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter & Nine Months period ended December 31, 2022**

(Rs. In Millions)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a. Wholesale	27.76	33.48	30.23	105.20	89.45	128.90
b. Retail	11,778.47	11,115.02	9,291.93	32,754.60	27,979.57	37,589.13
c. Diagnostic testing services	96.91	57.75	12.37	186.13	64.70	74.76
Revenue from Operations	11,903.14	11,206.25	9,334.53	33,045.93	28,133.72	37,792.79
2. Segment Results Profit						
a. Wholesale	0.66	0.80	0.68	2.60	1.96	2.89
b. Retail	365.61	290.93	400.47	896.06	1,494.14	1,820.45
c. Diagnostic testing services	(46.81)	(66.09)	(41.27)	(173.28)	(33.89)	(116.82)
Total	319.46	225.64	359.88	725.38	1,462.21	1,706.52
Less:						
Finance cost	(210.82)	(198.66)	(165.31)	(607.58)	(478.51)	(664.28)
Add:						
Interest Income	53.49	61.25	22.94	181.29	69.38	137.19
Total profit before tax	162.13	88.23	217.51	299.09	1,053.08	1,179.43
3. Segment assets						
a. Wholesale	9.22	8.21	6.16	9.22	6.16	3.27
b. Retail	22,728.20	22,008.52	16,894.30	22,728.20	16,894.30	18,855.45
c. Diagnostic testing services	1,586.62	1,366.07	665.63	1,586.62	665.63	816.36
d. Unallocated	2,928.77	2,877.87	6,523.36	2,928.77	6,523.36	6,265.40
Total	27,252.81	26,260.67	24,089.45	27,252.81	24,089.45	25,940.48
4. Segment liabilities						
a. Wholesale	-	-	-	-	-	-
b. Retail	11,899.09	11,197.75	9,734.95	11,899.09	9,734.95	11,313.72
c. Diagnostic testing services	757.38	662.60	255.48	757.38	255.48	454.23
d. Unallocated	-	-	148.52	-	148.52	-
Total	12,656.47	11,860.35	10,138.95	12,656.47	10,138.95	11,767.95



Notes to the Unaudited consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 03, 2023. These financial results have been subjected to review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to December 31, 2022	Unutilised amount as on December 31, 2022*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	2,826.06	1,845.64
ii) General Corporate Purposes	1,111.03	307.43	803.60
Total	5,782.73	3,133.49	2,649.24

* The aforesaid unutilised proceeds of Rs. 2,649.24 million have been placed as fixed deposits with bank.

3. The Board of Directors of the Company, at their meeting held on 10 January 2023, have approved a Scheme of arrangement between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary of the Company, wherein MHS is proposed to be merged with the Company from an appointed date of 01 April 2023. Management is in the process of seeking necessary approvals from the shareholders and the concerned regulators in respect of this Scheme.
4. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited
(formerly known as MedPlus Health Services Private Limited)



G. Madhukar Reddy

Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad
Date: February 03, 2023

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement") (in which are included financial information from an ESOP trust).
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



B S R & Associates LLP

Limited Review Report (*Continued*)
MedPlus Health Services Limited

contains any material misstatement.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231WW-100024



Arpan Jain

Partner

Hyderabad

03 February 2023

Membership No.: 125710

UDIN:23125710BGYPX9565

MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited)

CIN - L85110TG2006PLC051845

Regd. Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037.

Statement of Unaudited Standalone Financial Results for the Quarter & Nine Months period ended December 31, 2022

(Rs. in Millions)

S.No	Particulars	Quarter ended			Nine Months ended		Year ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	572.41	424.52	247.11	1,269.78	1,068.94	1,457.14
	Other income	40.66	42.65	11.22	136.98	33.30	95.41
I	Total income	613.07	467.17	258.33	1,406.76	1,102.24	1,552.55
	Expenses						
	Cost of materials consumed	67.28	52.21	35.50	168.63	141.85	193.56
	Purchases of stock-in-trade	357.53	251.05	177.13	769.69	763.13	972.12
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(17.20)	9.76	(18.10)	(25.84)	(34.26)	20.00
	Employee benefits expense	73.99	59.97	40.15	182.92	94.72	137.32
	Finance costs	17.90	14.58	6.35	44.96	14.45	26.31
	Depreciation and amortisation expense	42.40	32.02	12.41	99.81	27.69	46.32
	Other expenses	53.36	55.78	17.03	156.58	48.10	101.13
II	Total expenses	595.26	475.37	270.47	1,396.75	1,055.68	1,496.76
III	Profit / (Loss) before tax (I-II)	17.81	(8.20)	(12.14)	10.01	46.56	55.79
	Tax expense						
	- Current tax	11.61	-	-	11.61	-	-
	- Deferred tax	-	-	-	-	-	-
IV	Total tax expense	11.61	-	-	11.61	-	-
V	Net Profit / (Loss) after tax (III-IV)	6.20	(8.20)	(12.14)	(1.60)	46.56	55.79
	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss						
	- Re-measurement gain / (loss) on employee defined benefit plan	-	(1.06)	(0.16)	0.12	0.38	1.17
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
VI	Other comprehensive income / (loss) for the period / year, net of tax	-	(1.06)	(0.16)	0.12	0.38	1.17
VII	Total comprehensive income / (loss) for the period / year (V+VI)	6.20	(9.26)	(12.30)	(1.48)	46.94	56.96
VIII	Paid-up Capital						
	Equity Share Capital	238.60	238.60	238.60	238.60	238.60	238.60
IX	Other Equity						10,889.21
X	Earnings per equity share (for the period/quarter not annualised)						
	Basic (In absolute Rs.)	0.15	(0.07)	(0.11)	0.08	0.42	0.50
	Diluted (In absolute Rs.)	0.15	(0.07)	(0.11)	0.08	0.42	0.50
XI	Face value per share						
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00	2.00	2.00



Notes to the Unaudited standalone financial results:

1. The above unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 03, 2023. These financial results have been subjected to review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to December 31, 2022	Unutilised amount as on December 31, 2022*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	2,826.06	1,845.64
ii) General Corporate Purposes	1,111.03	307.43	803.60
Total	5,782.73	3,133.49	2,649.24

* The aforesaid unutilised proceeds of Rs. 2,649.24 million have been placed as fixed deposits with bank.

3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.
4. The Board of Directors of the Company, at their meeting held on 10 January 2023, have approved a Scheme of arrangement between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary of the Company, wherein MHS is proposed to be merged with the Company from an appointed date of 01 April 2023. Consequent adjustments will be made post receipt of shareholders and other regulatory approval as applicable.
5. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited
 (formerly known as MedPlus Health Services Private Limited)



G. Madhukar Reddy
 Managing Director and Chief Executive Officer
 DIN: 00098097



Place: Hyderabad
 Date: February 03, 2023



MedPlus Health Services Limited

Press Release: Feb 03, 2023

Consolidated Revenue has grown by 27.5% over previous year.

Gross store additions in Q3 FY23 of 246 stores. Our stores greater than 12 months have delivered a strong Store Level EBITDA margin of 10 % and Overall EBITDA margin of 4.9 %, thereby maintaining the trajectory of store maturity.

Our Diagnostic pilot in Hyderabad is progressing well with three full service centers and 100+ own Collection Centers.

Pharmacy Operations:

- Revenue growth of 6.2% over previous quarter and 27.5% over previous year.
- Gross addition of 246 stores in Q3 FY23.
- Gross margin of 21.7% in Q3 FY23.
- EBITDA margin of 3.5% in Q3 FY23, increased by 50 bps over previous quarter.